The two-step approach (strategy 2) had higher sensitivity than the fixed PSA threshold (strategy 1) at identifying prostate cancer cases (identified 68.2% versus 43.9% of cases), high-grade cancers (49.2% versus 40.3%), and deaths (67.0% versus 31.5%). The gene discussed is KLK3; the disease is cancer.